Index of reports
> Cases with Visual Field Defect (6)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cabergoline where reactions include visual field defect. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Cabergoline side effects in 30 year old male
Reported by a physician from France on 2012-03-30
Patient: 30 year old male
Reactions: Visual Field Defect, Condition Aggravated, Visual Pathway Disorder
Drug(s) suspected as cause:
Cabergoline
Possible Cabergoline side effects in 57 year old male
Reported by a health professional (non-physician/pharmacist) from France on 2012-03-30
Patient: 57 year old male
Reactions: Visual Field Defect, Visual Acuity Reduced, Condition Aggravated, Visual Pathway Disorder
Drug(s) suspected as cause:
Cabergoline
Other drugs received by patient: Testosterone Enanthate
Possible Cabergoline side effects in 64 year old male
Reported by a physician from France on 2012-03-29
Patient: 64 year old male
Reactions: Visual Field Defect, Prolactinoma, Neoplasm Progression, Condition Aggravated
Drug(s) suspected as cause:
Cabergoline
Other drugs received by patient: Levothyroxine Sodium; Testosterone Enanthate
Possible Cabergoline side effects in
Reported by a physician from France on 2011-11-18
Patient:
Reactions: Visual Field Defect, Toxicity To Various Agents, Visual Pathway Disorder
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cabergoline
Dosage: 3 mg/week
Indication: Prolactinoma
Cabergoline
Dosage: 0.5 mg/week
Possible Cabergoline side effects in
Reported by a physician from France on 2011-11-18
Patient:
Reactions: Visual Field Defect, Visual Pathway Disorder, Toxicity To Various Agents
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.25 mg/week
Cabergoline
Dosage: 3 mg/week
Indication: Prolactinoma
Possible Cabergoline side effects in
Reported by a physician from France on 2011-11-16
Patient:
Reactions: Visual Field Defect, Toxicity To Various Agents, Visual Pathway Disorder
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bromocriptine Mesylate
Dosage: 2.5 mg, / day
Indication: Prolactinoma
Bromocriptine Mesylate
Dosage: 2.5 mg/week
Cabergoline
Dosage: 1 mg/week
Cabergoline
Dosage: 0.5 mg/week
Indication: Prolactinoma
Other drugs received by patient: Levothyroxine Sodium
|